The European Research Infrastructure for Translational Medicine

ERICs & Innovation
AGM, 26 January 2021

EATRIS ERIC Case Study
Industry Collaboration
Making translation of scientific discoveries into biomedical products more effective to improve human health and quality of life.

To support researchers in developing their biomedical discoveries into novel translational tools and interventions for better health outcomes for society.
Industry collaboration – tailored approach

SME have different needs to large pharmaceuticals & biotech

Small-Medium Enterprises need
- Expert support to develop their product
- Speed to get to next inflection point

Large companies seek
- Systematic approach to engagement
- New product and tools ideas

They all need to work with organized, professional partners

Broad range of user types - examples

- SME (28%)
- Large Pharma (9%)
- Funder (14%)
- Academia (49%)

User requests EATRIS ERIC 2014-2020
Dr Rogier Thurlings, Rheumatologist, Radboudumc, The Netherlands (EATRIS member)

“We are very positive about the collaboration in the GSK Immune Inflammation Imaging Hub. The Hub forms a unique platform for interaction between academia and industry. Its dedication towards clinical implementation increases the chance that our patients profit from imaging-guided drug development.”
Immuno-Inflammation Imaging Hub

Working with global pharmaceuticals creating better research tools

- Imaging of inflammation & infection
- Supporting drug development
- Multinational, multiparty collaboration
- EATRIS secretariat
- Legal support
- Tailored project agreements
Imaging Hub - outputs so far

- 3 years into collaboration
- 12 active projects (3 preclinical, 2 clinical, 1 co-funded PhD, 2 scouting, 4 public co-funded applications)
- 15 molecular (tracer) targets under exploration
- 8 organisations/legal entities involved
- More than 20 legal agreements established
To Private Partners

- ERIC acts as trusted third party – single point of contact & management
- Increased quality and execution of research components
- Access to a network of external (clinical) experts
- Enhanced innovation capacity for industry

To Public Partners

- Co-funding opportunities to develop new research methods
- Faster application of academic research towards patients
- Multidisciplinary collaboration with company scientists & expertise
Working with research funders

As a service to research funders, EATRIS performs a Translational Assessment to analyse the translational potential of research project considered for funding.

- Creates early awareness of potential bottlenecks
- Identify risks & suggest work-arounds to optimize study plan and patient benefit
- Brings confidence to the funder in decision making
Optimising patient benefit

✓ 47 projects assessed
✓ 20 – 45 person hours required per project
✓ 5 – 7 experts involved per project

“The translational assessment performed in 2019 by EATRIS […] was very useful in making an informed decision to provide financial support to Yumen Bionics that develops an innovative bionic arm to improve the quality of life of Duchenne patients.”

“(Long-term) partnerships:

- Yumen Bionics
- Dutch Arthritis Society
- ZonMw
- European Joint Programme Rare Diseases

“The EATRIS translational assessment provided valuable insights in the health economics aspects of our prototype product. The expert insights, […] were a confirmation of our endeavor to address the most pressing medical need for the patients…”.
For additional questions

- Martin de Kort, Sr. Scientific Program Manager
  martindekort@eatris.eu

- Chris Tieken, Business Development
  christieken@eatris.eu

- EATRIS

- @EatrisEric

- www.eatris.eu